Polypharmacy: Adding nonsteroidal MRAs, when and how

Media formats available:

Causal relationship between elevated Lp(a) levels and CKD risk
Causal relationship between elevated Lp(a) levels and CKD risk
EAS 2024
Causal relationship between elevated Lp(a) levels and CKD risk
- Anne Langsted, MD, PhD
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
ACC.24
Increasing the use of SGLT2i and GLP-1RA with a remote program in T2D and high CV or kidney risk
- Alexander J. Blood, MD
Prescribing and monitoring novel potassium binders for optimizing RAASi therapy in HF
Prescribing and monitoring novel potassium binders for optimizing RAASi therapy in HF
Tackling the risk of hyperkalemia through guideline-recommended heart failure therapy
Prescribing and monitoring novel potassium binders for optimizing RAASi therapy in HF
- Aaron Wong, MD
The key role of RAASi therapy in patients with HF
The key role of RAASi therapy in patients with HF
Tackling the risk of hyperkalemia through guideline-recommended heart failure therapy
The key role of RAASi therapy in patients with HF
- Shelley Zieroth, MD

PACE-CME